A Comprehensive Monograph on Nivolumab (Opdivo®): Pharmacology, Clinical Efficacy, and Therapeutic Landscape

Executive Summary & Drug Profile

Overview of Nivolumab

Nivolumab represents a cornerstone of modern immuno-oncology, a therapeutic class that has fundamentally altered the treatment paradigm for a multitude of malignancies. Marketed under the brand name Opdivo®, Nivolumab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody developed by Bristol Myers Squibb.[1] It functions as an immune checkpoint inhibitor by selectively targeting the programmed death receptor-1 (PD-1).[2] First granted approval by the U.S. Food and Drug Administration (FDA) in December 2014, Nivolumab was a pioneering agent in its class and has since garnered approvals for an exceptionally broad range of solid tumors and hematologic cancers.[4]

The therapeutic principle of Nivolumab is not to attack cancer cells directly, but to block a key inhibitory signal used by tumors to evade the host immune system. By binding to the PD-1 receptor on T-cells, Nivolumab prevents their deactivation, thereby unleashing a patient's own T-cells to recognize and eliminate malignant cells.[2] This mechanism has led to durable, long-term responses and significant improvements in overall survival in cancers that were previously considered difficult to treat. However, this potentiation of the immune system is also responsible for a unique and characteristic spectrum of immune-related adverse events (irAEs), which require specialized clinical management.[4] The drug's development and expanding applications, both as a monotherapy and in combination with other agents like the CTLA-4 inhibitor ipilimumab, underscore its central role in the contemporary oncologic armamentarium.

Core Drug Identification and Properties

The fundamental identifiers and physicochemical properties of Nivolumab provide the foundational data for understanding its pharmacological behavior and clinical application. These core attributes are consolidated from numerous sources into a single, comprehensive reference profile.

Table 1: Nivolumab Drug Profile Summary

Attribute	Details	Source(s)
Generic Name	Nivolumab	1
Brand Names	Opdivo® (intravenous), Opdivo Qvantig™ (subcutaneous formulation with hyaluronidase-nvhy), Opdualag™ (fixed-dose combination with relatlimab)	2
Developer/Manufacturer	Bristol Myers Squibb (developed in collaboration with Ono Pharmaceutical)	1
DrugBank ID	DB09035	1
Type	Biotech, Protein-Based Therapy, Monoclonal Antibody (mAb)	1
CAS Number	946414-94-4	[User Query]
Chemical Formula	C6362​H9862​N1712​O1995​S42​	1
Average Molecular Weight	143,597.38 Da	1
Other Names/Codes	BMS-936558, ONO-4538, MDX-1106, NIVO	10

Pharmacology and Mechanism of Action

Molecular Target: The PD-1/PD-L1 Immune Checkpoint Axis

To comprehend the function of Nivolumab, it is essential to first understand its molecular target: the Programmed Death-1 (PD-1) pathway. PD-1, also known as CD279, is a critical inhibitory receptor, or "checkpoint," expressed on the surface of activated T-cells, B-cells, and other immune cells like natural killer (NK) cells and monocytes.[2] Its primary physiological role is to act as a brake on the immune system. When PD-1 binds to its ligands—Programmed Death-Ligand 1 (PD-L1, also known as B7-H1 or CD274) and Programmed Death-Ligand 2 (PD-L2, also known as B7-DC or CD273)—it transmits an inhibitory signal into the T-cell.[10] This signal dampens T-cell proliferation, cytokine production, and cytotoxic activity. This regulatory mechanism is vital for maintaining self-tolerance, preventing the immune system from attacking healthy tissues (autoimmunity), and resolving inflammation after an infection has been cleared.[4]

Many cancer cells have evolved to exploit this natural regulatory pathway to shield themselves from immune attack. Tumors can upregulate the expression of PD-L1 on their cell surface or induce its expression on non-cancerous cells within the tumor microenvironment, such as macrophages and myeloid-derived suppressor cells.[2] When tumor-infiltrating lymphocytes (TILs) that express PD-1 encounter these PD-L1-positive cells, the inhibitory PD-1 pathway is engaged. This leads to a state of T-cell "exhaustion" or anergy, effectively deactivating the anti-tumor immune response and allowing the cancer to grow and metastasize unimpeded.[4]

Nivolumab's Mechanism of Action

Nivolumab is a genetically engineered, fully human monoclonal antibody of the immunoglobulin G4 (IgG4) kappa isotype.[1] It was developed through the immunization of transgenic mice engineered to contain human immunoglobulin loci, and the resulting antibody was grafted onto a human IgG4 constant region.[1] Nivolumab functions by directly and potently disrupting the tumor's primary shield against immune attack.

The antibody binds with high specificity and affinity (dissociation constant, KD​=2.6 nmol/L) to the human PD-1 receptor.[10] This binding physically obstructs the interaction between PD-1 and its ligands, PD-L1 and PD-L2.[2] By preventing this engagement, Nivolumab effectively "releases the brakes" on the immune system. It blocks the inhibitory signal that would otherwise be delivered to the T-cell, thereby reversing PD-1 pathway-mediated immune suppression.[3] This blockade restores and enhances T-cell function, including proliferation, cytokine release, and the ability to recognize and mount a cytotoxic attack against tumor cells, ultimately facilitating tumor rejection.[2] This immunological "memory" may persist even after treatment has ceased, potentially leading to durable, long-term responses.[13]

The bioengineering of Nivolumab is a critical determinant of its function and safety profile. The selection of the IgG4 isotype is a deliberate design choice. Unlike the IgG1 isotype, which possesses strong effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), the IgG4 isotype is relatively inert. This ensures that Nivolumab does not inadvertently destroy the very T-cells it is designed to activate. Furthermore, Nivolumab incorporates a stabilizing S228P mutation in its hinge region.[1] This mutation prevents a phenomenon known as Fab-arm exchange, where IgG4 molecules can swap half-molecules in vivo, which would otherwise create unpredictable bispecific antibodies and reduce therapeutic consistency. This elegant molecular design—an inert IgG4 backbone with an S228P mutation—ensures that Nivolumab functions as a pure signaling blocker, focused solely on checkpoint inhibition.

This design choice has a direct and profound causal link to the drug's entire clinical profile. The efficacy of Nivolumab arises exclusively from unleashing the patient's T-cells, not from any direct cytotoxic action of the antibody itself. Consequently, the characteristic safety profile, defined by a spectrum of immune-related adverse events (irAEs), is not a result of off-target drug effects. Rather, the irAEs are the direct, on-target, and unavoidable consequence of a successfully reinvigorated and now potentially overactive systemic T-cell response that can target healthy tissues.[4] The inflammatory nature of the side effects, such as pneumonitis, colitis, and endocrinopathies, is a mirror image of the drug's intended mechanism of action.

Pharmacokinetics (PK) and Pharmacodynamics (PD)

The pharmacokinetic and pharmacodynamic properties of Nivolumab dictate its dosing schedule and clinical behavior.

Absorption and Distribution

Nivolumab is administered via intravenous infusion (or subcutaneously in its newer formulation, Opdivo Qvantig) and does not undergo oral absorption.4 In clinical studies, it exhibits linear pharmacokinetics, meaning that its peak concentration (

Cmax​) and total exposure (area under the curve, AUC) increase in direct proportion to the dose administered, within the range of 0.1 to 10 mg/kg.[10] Following intravenous infusion, the time to reach peak plasma concentration (

Tmax​) is between 1 and 4 hours.[4] The mean volume of distribution at steady state (

Vss​) is approximately 6.8 L, which indicates that the drug's distribution is largely confined to the plasma and the interstitial fluid of well-perfused organs, consistent with a large molecule like a monoclonal antibody.[4]

Metabolism and Elimination

As a protein-based therapeutic, Nivolumab is not metabolized by the cytochrome P450 (CYP450) enzyme system in the liver, which is the primary route for small-molecule drugs. Instead, it is presumed to be cleared from the body through catabolism, where it is broken down into smaller peptides and individual amino acids by proteolytic pathways throughout the body.4 This is the standard elimination route for endogenous immunoglobulins. Nivolumab clearance has been shown to increase with increasing body weight, which was the initial rationale for weight-based dosing.12 The elimination half-life (

t1/2​) is long, approximately 25 days, which is a key factor enabling less frequent dosing schedules.[4] When administered every 2 weeks, steady-state concentrations are achieved by 12 weeks, with a systemic accumulation of approximately 3.7-fold.[16]

Pharmacodynamics

The pharmacodynamic effect of Nivolumab is defined by its target engagement. Studies have shown that Nivolumab binds to the PD-1 receptor with high affinity and achieves durable receptor occupancy on circulating CD3+ T-cells.10 This occupancy appears to be saturated at clinically relevant doses. At doses of 0.3 mg/kg and higher, Nivolumab achieves a mean peak PD-1 receptor occupancy of 85% within 4 to 24 hours post-infusion. This high level of occupancy is sustained, with a plateau of approximately 72% observed at 57 days and beyond, even as serum drug levels decline.10

The relationship between Nivolumab's PK/PD profile provides a strong pharmacological rationale for its dosing evolution. The initial dosing was weight-based (e.g., 3 mg/kg every 2 weeks).[17] However, the pharmacodynamic data demonstrating that receptor occupancy is saturated at very low doses, combined with the long half-life, suggested that a fixed dose could provide equivalent target engagement for the vast majority of patients, regardless of weight. This understanding underpinned the transition to simpler, more convenient flat-dose regimens, such as 240 mg every 2 weeks or 480 mg every 4 weeks.[6] This saturation effect is also the key pharmacological basis for ongoing clinical research into alternative dosing strategies. If the PD-1 target is fully engaged for a prolonged period, it implies that for a significant portion of the dosing interval, patients may have "excess" drug in circulation that is not contributing further to the biological effect. This has opened the door for cost-effectiveness analyses and clinical trials exploring lower doses or extended dosing intervals, which could potentially reduce treatment costs, patient burden, and possibly toxicity, without compromising clinical efficacy.[20] A small study investigating a low 40 mg flat dose of Nivolumab, for instance, reported comparable response rates to conventional doses but with better tolerability, providing preliminary real-world evidence to support this hypothesis.[20]

Global Regulatory Landscape and Approval History

Nivolumab's path to becoming a global standard of care is marked by a rapid succession of regulatory approvals from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). While there is broad alignment, notable differences in their approval trajectories and labeling requirements reflect distinct regulatory philosophies.

U.S. Food and Drug Administration (FDA) Approval Trajectory

Nivolumab's journey in the United States began on December 22, 2014, with an accelerated approval for the treatment of patients with unresectable or metastatic melanoma who had progressed on prior therapy.[5] This landmark decision marked the arrival of a new class of immunotherapy. From this initial foothold, the drug's indications expanded at an unprecedented pace, transforming the treatment landscape for numerous cancers.

Key milestones in its FDA approval history include:

• Non-Small Cell Lung Cancer (NSCLC): A major expansion occurred in March 2015 with approval for metastatic squamous NSCLC, followed by non-squamous NSCLC in October 2015, both in the second-line setting after platinum-based chemotherapy failure.[5]
• Renal Cell Carcinoma (RCC): Approved in November 2015 for advanced RCC in patients who had received prior anti-angiogenic therapy.[5]
• Classical Hodgkin Lymphoma (cHL): Gained approval in May 2016 for relapsed or refractory cHL, an indication where it showed remarkable activity.[5]
• Head and Neck Cancer (SCCHN): Approved in November 2016 for recurrent or metastatic SCCHN progressing after platinum-based therapy.[5]
• Urothelial Carcinoma: Received its first approval for bladder cancer in February 2017 for platinum-refractory patients.[19]
• Colorectal and Hepatocellular Cancers: Further expanded into gastrointestinal cancers with approvals for MSI-H/dMMR colorectal cancer (August 2017) and second-line hepatocellular carcinoma (September 2017).[5]
• Malignant Pleural Mesothelioma: Approved in October 2020 as a first-line treatment in combination with ipilimumab, providing a new standard of care.[5]
• Upper GI Cancers: A series of approvals from 2020 to 2022 established its role in gastric, gastroesophageal junction (GEJ), and esophageal cancers in various settings.[2]

A crucial element of Nivolumab's strategy has been the development of combination therapies. The pairing of Nivolumab with the CTLA-4 inhibitor ipilimumab (Yervoy®) proved synergistic and became a cornerstone for first-line approvals in melanoma, RCC, NSCLC, and mesothelioma.[2] Similarly, the combination with the tyrosine kinase inhibitor cabozantinib was approved for first-line RCC.[5]

More recently, a significant evolution in drug delivery was achieved with the approval of Opdivo Qvantig™, a subcutaneous formulation of Nivolumab co-formulated with the enzyme hyaluronidase-nvhy.[8] Approved based on the non-inferior pharmacokinetic and efficacy results of the CheckMate-67T trial, this formulation reduces administration time from a 30-minute infusion to a 3-5 minute injection, greatly enhancing patient convenience and reducing healthcare resource utilization.[14]

The regulatory landscape is also dynamic, as evidenced by the voluntary withdrawal of certain accelerated approvals when confirmatory trials did not meet their primary endpoints, such as for monotherapy in post-sorafenib hepatocellular carcinoma and for small cell lung cancer, reflecting a commitment to evidence-based practice.[5]

European Medicines Agency (EMA) Marketing Authorisation

Nivolumab received its first marketing authorisation from the EMA in June 2015 for advanced melanoma.[2] Its approval trajectory in the European Union has largely paralleled that in the U.S., covering a similar breadth of cancers including NSCLC, RCC, cHL, SCCHN, urothelial carcinoma, and various GI malignancies.[27] However, a critical distinction lies in the EMA's often more stringent application of predictive biomarkers to define eligible patient populations.[30]

This divergence in regulatory philosophy has significant clinical implications. For several indications where the FDA granted broad approval, the EMA mandated biomarker testing to enrich the patient population for those most likely to benefit. Key examples include:

• Oesophageal Squamous Cell Carcinoma (OSCC): First-line treatment with Nivolumab combinations (with ipilimumab or chemotherapy) is restricted to patients with tumor cell PD-L1 expression ≥1%.[27]
• Gastric, GEJ, or Oesophageal Adenocarcinoma: First-line treatment with Nivolumab plus chemotherapy is limited to patients with HER2-negative tumors that express PD-L1 with a Combined Positive Score (CPS) ≥5.[28]
• Neoadjuvant NSCLC: The perioperative regimen is approved for patients with resectable NSCLC whose tumors have PD-L1 expression ≥1%.[29]

This contrast highlights differing approaches to risk-benefit assessment. The FDA has frequently prioritized broader patient access based on the overall benefit observed in the total trial population, allowing for greater physician discretion. The EMA, conversely, has more often favored a tailored approach, using biomarkers to define a more specific population where the therapeutic benefit is most pronounced, thereby optimizing the risk-benefit ratio. This creates different standards of care, diagnostic workflows, and patient access pathways between the two regions. In the EU, a physician is often mandated by the label to perform a specific biomarker test and can only prescribe Nivolumab if the patient meets the required threshold. In the U.S., for some of the same indications, the physician may have the discretion to prescribe the drug regardless of the biomarker status, although clinical guidelines and payer policies often influence this decision. This underscores the ongoing global debate regarding the optimal implementation of biomarkers like PD-L1 in clinical practice.

Key Regulatory Tables

The following tables provide a structured summary of the approved indications for Nivolumab in the United States and the European Union, facilitating a direct comparison of the two regulatory landscapes.

Table 2: FDA-Approved Indications for Nivolumab (Opdivo®) (as of late 2024)

Cancer Type	Line of Therapy / Setting	Patient Population Details	Approved Regimen	Source(s)
Melanoma	First-Line, Unresectable or Metastatic	Adult and pediatric (≥12 years)	Nivolumab monotherapy OR Nivolumab + Ipilimumab	19
	Adjuvant	Completely resected Stage IIB, IIC, III, or IV; Adult and pediatric (≥12 years)	Nivolumab monotherapy	1
Non-Small Cell Lung Cancer (NSCLC)	Neoadjuvant	Resectable (tumors ≥4 cm or node positive)	Nivolumab + Platinum-doublet chemotherapy	1
	First-Line, Metastatic	PD-L1 ≥1%, no EGFR/ALK aberrations	Nivolumab + Ipilimumab	19
	First-Line, Metastatic or Recurrent	No EGFR/ALK aberrations	Nivolumab + Ipilimumab + 2 cycles of platinum-doublet chemotherapy	1
	Second-Line+, Metastatic	Progression on/after platinum-based chemotherapy	Nivolumab monotherapy	19
Malignant Pleural Mesothelioma	First-Line, Unresectable	Adults	Nivolumab + Ipilimumab	2
Renal Cell Carcinoma (RCC)	First-Line, Advanced	Intermediate or poor risk	Nivolumab + Ipilimumab	19
	First-Line, Advanced	All risk groups	Nivolumab + Cabozantinib	5
	Second-Line+, Advanced	After prior anti-angiogenic therapy	Nivolumab monotherapy	19
Classical Hodgkin Lymphoma (cHL)	Relapsed/Refractory	After autologous HSCT and brentuximab vedotin, or ≥3 lines of therapy including autologous HSCT	Nivolumab monotherapy	6
Head and Neck Cancer (SCCHN)	Second-Line+, Recurrent or Metastatic	Progression on/after platinum-based therapy	Nivolumab monotherapy	1
Urothelial Carcinoma	First-Line, Unresectable or Metastatic	Adults	Nivolumab + Cisplatin + Gemcitabine	1
	Adjuvant	High-risk, post-radical resection	Nivolumab monotherapy	1
	Second-Line+, Locally Advanced or Metastatic	Progression during/following platinum-containing chemotherapy	Nivolumab monotherapy	19
Colorectal Cancer (CRC)	First-Line, Unresectable or Metastatic	MSI-H or dMMR; Adult and pediatric (≥12 years)	Nivolumab + Ipilimumab	1
	Second-Line+, Metastatic	MSI-H or dMMR; Progression after fluoropyrimidine, oxaliplatin, and irinotecan	Nivolumab monotherapy OR Nivolumab + Ipilimumab	1
Hepatocellular Carcinoma (HCC)	First-Line, Unresectable or Metastatic	Adults	Nivolumab + Ipilimumab	1
	Second-Line+, Unresectable or Metastatic	Previously treated with sorafenib	Nivolumab + Ipilimumab	1
Esophageal/GEJ Cancer	Adjuvant	Resected esophageal or GEJ cancer with residual pathologic disease post-neoadjuvant CRT	Nivolumab monotherapy	1
	First-Line, Advanced/Metastatic ESCC	Adults	Nivolumab + Chemotherapy OR Nivolumab + Ipilimumab	1
	Second-Line+, Advanced/Metastatic ESCC	After prior fluoropyrimidine- and platinum-based chemotherapy	Nivolumab monotherapy	19
Gastric/GEJ/Esophageal Adenocarcinoma	First-Line, Advanced or Metastatic	Adults	Nivolumab + Fluoropyrimidine- and platinum-containing chemotherapy	19

Table 3: EMA-Approved Indications for Nivolumab (Opdivo®) (as of late 2024)

Cancer Type	Line of Therapy / Setting	Patient Population Details (Biomarker Requirements Highlighted)	Approved Regimen	Source(s)
Melanoma	First-Line, Advanced	Adults and adolescents (≥12 years). Combination benefit primarily in low tumor PD-L1 expression.	Nivolumab monotherapy OR Nivolumab + Ipilimumab	27
	Adjuvant	Stage IIB, IIC, or resected stage III/IV; Adults and adolescents (≥12 years)	Nivolumab monotherapy	28
Non-Small Cell Lung Cancer (NSCLC)	Neoadjuvant	Resectable, high-risk, tumor PD-L1 expression ≥ 1%	Nivolumab + Platinum-based chemotherapy	27
	First-Line, Metastatic	No sensitizing EGFR/ALK mutation	Nivolumab + Ipilimumab + 2 cycles of platinum-based chemotherapy	27
	Second-Line+, Locally Advanced or Metastatic	After prior chemotherapy	Nivolumab monotherapy	27
Malignant Pleural Mesothelioma	First-Line, Unresectable	Adults	Nivolumab + Ipilimumab	27
Renal Cell Carcinoma (RCC)	First-Line, Advanced	Intermediate/poor-risk	Nivolumab + Ipilimumab	27
	First-Line, Advanced	All risk groups	Nivolumab + Cabozantinib	27
	Second-Line+, Advanced	After prior therapy	Nivolumab monotherapy	27
Classical Hodgkin Lymphoma (cHL)	Relapsed/Refractory	After ASCT and brentuximab vedotin	Nivolumab monotherapy	27
Head and Neck Cancer (SCCHN)	Second-Line+, Recurrent or Metastatic	Progressing on/after platinum-based therapy	Nivolumab monotherapy	27
Urothelial Carcinoma	First-Line, Unresectable or Metastatic	Adults	Nivolumab + Cisplatin + Gemcitabine	27
	Adjuvant (MIUC)	High-risk, post-radical resection, tumor cell PD-L1 expression ≥ 1%	Nivolumab monotherapy	27
	Second-Line+, Locally Advanced Unresectable or Metastatic	After failure of prior platinum-containing therapy	Nivolumab monotherapy	27
Colorectal Cancer (CRC)	First-Line or Second-Line+	dMMR or MSI-H, metastatic	Nivolumab + Ipilimumab	27
Hepatocellular Carcinoma (HCC)	First-Line, Unresectable or Advanced	Adults	Nivolumab + Ipilimumab	27
Oesophageal Squamous Cell Carcinoma (OSCC)	First-Line, Advanced/Metastatic	Tumor cell PD-L1 expression ≥ 1%	Nivolumab + Ipilimumab OR Nivolumab + Chemotherapy	27
	Second-Line+, Advanced/Metastatic	After prior fluoropyrimidine- and platinum-based chemotherapy	Nivolumab monotherapy	27
Oesophageal/GEJ Cancer	Adjuvant	Residual pathologic disease following prior neoadjuvant CRT	Nivolumab monotherapy	27
Gastric/GEJ/Oesophageal Adenocarcinoma	First-Line, Advanced or Metastatic	HER2-negative, tumors express PD-L1 with a CPS ≥ 5	Nivolumab + Chemotherapy	28

Clinical Efficacy and Therapeutic Applications

The broad utility of Nivolumab across numerous cancer types is substantiated by a portfolio of large, randomized clinical trials, primarily from the CheckMate clinical development program. These studies have consistently demonstrated clinically meaningful improvements in key efficacy endpoints such as Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR).

Melanoma

Nivolumab has revolutionized the treatment of advanced melanoma.

• Unresectable or Metastatic Melanoma: In the first-line setting for patients with BRAF wild-type tumors, the CheckMate 066 trial demonstrated the superiority of Nivolumab monotherapy over dacarbazine chemotherapy. At one year, the OS rate was 72.9% for the Nivolumab group compared to 42.1% for the dacarbazine group, a landmark improvement.[32] The CheckMate 067 trial further defined the role of combination therapy, comparing Nivolumab plus ipilimumab against each agent as monotherapy. The combination yielded a significantly longer median PFS of 11.5 months, compared to 6.9 months for Nivolumab alone and 2.9 months for ipilimumab alone. This benefit was particularly pronounced in patients whose tumors had low PD-L1 expression, establishing the combination as a key first-line option.[32]
• Adjuvant Therapy: In the adjuvant setting for patients with completely resected high-risk melanoma, Nivolumab has also become a standard of care. It was initially approved for resected Stage III or IV melanoma based on demonstrating superior recurrence-free survival compared to ipilimumab.[2] This indication was later expanded to include patients with resected Stage IIB or IIC melanoma after Nivolumab showed a significant benefit over placebo in reducing the risk of recurrence.[1] Standard dosing for adjuvant therapy is 240 mg IV every 2 weeks or 480 mg IV every 4 weeks for up to one year.[18]

Non-Small Cell Lung Cancer (NSCLC)

Nivolumab provides a critical treatment option across various stages and settings of NSCLC.

• Second-Line Treatment: Initial approvals were based on studies showing superior OS compared to the standard chemotherapy docetaxel in patients with both squamous and non-squamous NSCLC who had progressed after first-line platinum-based chemotherapy.[5]
• First-Line Treatment: For treatment-naïve patients, Nivolumab is approved in combination regimens. For patients whose tumors express PD-L1 (≥1%) and lack EGFR or ALK mutations, Nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks) is an approved chemotherapy-sparing option.[19] For patients regardless of PD-L1 status, a regimen of Nivolumab (360 mg every 3 weeks) plus ipilimumab (1 mg/kg every 6 weeks) combined with two cycles of platinum-doublet chemotherapy is also approved.[1]
• Peri-operative (Neoadjuvant/Adjuvant) Treatment: The CheckMate -816 trial was a practice-changing study for resectable NSCLC. It showed that three cycles of neoadjuvant Nivolumab plus platinum-doublet chemotherapy led to a significantly higher rate of pathologic complete response (24.0% vs. 2.2%) and a longer median event-free survival compared to chemotherapy alone.[35] This led to approvals in both the U.S. and EU for this peri-operative approach, typically dosed at 360 mg IV every 3 weeks with chemotherapy for 3-4 cycles before surgery, sometimes followed by adjuvant Nivolumab monotherapy.[1]

Renal Cell Carcinoma (RCC)

Nivolumab is a key component of first- and second-line therapy for advanced RCC.

• Previously Treated RCC: In patients with advanced RCC who had progressed on prior anti-angiogenic therapy, Nivolumab monotherapy demonstrated a significant OS benefit over the mTOR inhibitor everolimus, leading to its approval in the second-line setting.[5] The standard monotherapy dose is 240 mg IV every 2 weeks or 480 mg IV every 4 weeks.[18]
• First-Line RCC: Nivolumab is approved in two distinct first-line combination regimens. The CheckMate -214 trial established Nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for 4 doses, followed by Nivolumab monotherapy, as a standard of care for patients with intermediate- or poor-risk advanced RCC.[25] For patients across all risk groups, the combination of Nivolumab (240 mg every 2 weeks or 480 mg every 4 weeks) with the oral tyrosine kinase inhibitor cabozantinib is also approved, offering another potent first-line option.[5]

Urothelial Carcinoma

Nivolumab has indications in both metastatic and adjuvant settings for urothelial carcinoma, the most common form of bladder cancer.[2]

• Metastatic Disease: In the second-line setting, Nivolumab is approved as a monotherapy for patients with locally advanced or metastatic urothelial carcinoma who have progressed during or after platinum-containing chemotherapy.[6] More recently, it was approved as a first-line treatment for unresectable or metastatic disease in combination with standard chemotherapy (cisplatin and gemcitabine), providing a new option for treatment-naïve patients.[1]
• Adjuvant Treatment: For patients with high-risk muscle-invasive urothelial carcinoma who have undergone radical resection, adjuvant Nivolumab monotherapy is approved to reduce the risk of disease recurrence.[1]

Colorectal Cancer (CRC)

The indication for Nivolumab in colorectal cancer is a prime example of biomarker-driven therapy. Its use is strictly limited to a specific molecular subtype: tumors that are microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). These tumors have an impaired ability to repair DNA errors, leading to a high mutational burden and making them particularly susceptible to immune checkpoint inhibition. Nivolumab is approved for this patient population (adults and pediatrics ≥12 years) as a monotherapy after progression on standard chemotherapies, or as a first-line treatment in combination with ipilimumab for unresectable or metastatic disease.[1]

Upper GI Cancers (Esophageal, Gastric, GEJ)

Nivolumab has a complex but important role in various upper gastrointestinal malignancies. It is approved in multiple combinations and lines of therapy for esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma, gastric cancer, and gastroesophageal junction (GEJ) cancer. Regimens include combinations with chemotherapy (fluoropyrimidine- and platinum-containing) or with ipilimumab, often as first-line treatment for advanced or metastatic disease.[1] It is also approved as an adjuvant therapy for resected esophageal or GEJ cancer in patients with residual disease after neoadjuvant chemoradiotherapy.[25] As noted previously, EMA approvals in this space are frequently contingent on PD-L1 expression status.[27]

Other Malignancies

• Classical Hodgkin Lymphoma (cHL): Nivolumab has shown remarkable efficacy in relapsed/refractory cHL. Reed-Sternberg cells, the hallmark of cHL, often have amplification of chromosome 9p24.1, which encodes the PD-L1 and PD-L2 ligands, leading to their constitutive expression and creating a strong biological rationale for PD-1 blockade. An early study reported an impressive objective response rate of 87%.[2] It is approved for patients who have relapsed after autologous stem cell transplant and other lines of therapy.[25]
• Malignant Pleural Mesothelioma: The combination of Nivolumab and ipilimumab is the first immunotherapy regimen approved for the first-line treatment of adults with unresectable malignant pleural mesothelioma, offering a significant advancement over chemotherapy alone.[2]
• Hepatocellular Carcinoma (HCC): For patients with unresectable or metastatic HCC, the combination of Nivolumab and ipilimumab is approved as a first-line treatment option.[1]

Safety, Tolerability, and Risk Management

While Nivolumab has transformed cancer treatment, its unique mechanism of action gives rise to a distinct safety profile characterized by immune-related adverse events (irAEs). Effective management of these toxicities is paramount for patient safety and optimal treatment outcomes.

Overview of the Safety Profile

The most frequently reported adverse reactions across clinical trials for Nivolumab monotherapy are generally low-grade and include fatigue, musculoskeletal pain, rash, pruritus, diarrhea, nausea, and cough.[6] When used in combination with ipilimumab, the incidence and severity of adverse events increase significantly, with fatigue, diarrhea, rash, and pruritus being very common.[6] Compared to the classic cytotoxic effects of chemotherapy (e.g., myelosuppression, alopecia), Nivolumab is often described as being well-tolerated.[34] However, this general tolerability is punctuated by the risk of severe, and sometimes life-threatening, inflammatory events that can affect any organ system.

Immune-Related Adverse Events (irAEs): A Mechanistic Deep Dive

Immune-related adverse events are a direct consequence of Nivolumab's on-target mechanism. By removing the PD-1 checkpoint, the drug potentiates a generalized T-cell response that, in some patients, can lose its specificity for tumor cells and begin to attack healthy tissues, resulting in autoimmune-like inflammatory conditions.[4] The risk of severe irAEs is substantially higher with combination immunotherapy (e.g., Nivolumab + Ipilimumab) than with Nivolumab monotherapy. A systematic overview of the most critical irAEs is presented in Table 5.

Table 5: Summary of Key Immune-Related Adverse Events (irAEs) and Comparative Incidence

Immune-Related Adverse Event	Incidence (Any Grade) - Nivolumab Monotherapy	Incidence (Grade 3-4) - Nivolumab Monotherapy	Incidence (Any Grade) - Nivolumab + Ipilimumab	Incidence (Grade 3-4) - Nivolumab + Ipilimumab	Key Management Notes	Source(s)
Pneumonitis	3.1%	1.0%	7-9%	2.2-4.0%	Can be fatal. Higher risk with prior thoracic radiation. Monitor for cough, dyspnea, chest pain.	6
Colitis	2.9%	1.7%	9-25%	3.7-14%	Can lead to perforation. Monitor for diarrhea, abdominal pain, blood/mucus in stool.	6
Hepatitis	1.8%	1.5%	7-15%	4.9-13.4%	Can lead to fulminant hepatic failure. Monitor LFTs. Higher risk with cabozantinib combo.	6
Endocrinopathies	Variable	<1-1%	Variable	<1-5%	Often permanent, requiring hormone replacement. Includes thyroiditis, hypo/hyperthyroidism, hypophysitis, adrenal insufficiency, and Type 1 diabetes.	4
Nephritis & Renal Dysfunction	1.2%	0.6%	~5%	~2%	Monitor for elevated creatinine. Pathology often shows tubulointerstitial nephritis.	6
Dermatologic Reactions	~20-40%	1.1%	~40-60%	3.5-4.8%	Common but can be severe (SJS/TEN). Monitor for severe or blistering rash.	6
Myocarditis	Rare (<0.1%)	Rare	Rare (<0.5%)	Rare	Very uncommon but associated with high fatality rate. Monitor for chest pain, arrhythmias, signs of heart failure.	4

Management of Adverse Events

The cornerstone of irAE management is early recognition, patient education, and prompt intervention. Patients must be educated to report any new or worsening symptoms immediately, as these events can occur at any time during treatment and even months after the last dose.[38]

The standard management algorithm is grade-dependent:

• Grade 1: Treatment may often continue with close monitoring and symptomatic care.
• Grade 2 (Moderate): Treatment is typically withheld. If symptoms do not resolve quickly, systemic corticosteroids (e.g., prednisone at a dose of 0.5-1 mg/kg/day or equivalent) are initiated.
• Grade 3 (Severe) & Grade 4 (Life-threatening): Treatment is permanently discontinued (with some exceptions for endocrinopathies that are controlled with hormone replacement). High-dose intravenous corticosteroids (e.g., methylprednisolone 1-2 mg/kg/day) are administered immediately.[4]

Once symptoms improve to Grade 1 or less, the corticosteroid dose is slowly tapered over a period of at least one month to prevent recurrence.[6] For irAEs that are refractory to corticosteroids, second-line immunosuppressive agents such as infliximab (for colitis or hepatitis) or mycophenolate mofetil may be required.[4]

Specific Warnings and Precautions

• Infusion-Related Reactions: While uncommon (<1% to 6.4% depending on infusion time and regimen), severe infusion reactions can occur. Management involves immediately stopping the infusion and providing appropriate medical supportive care. Patients with mild to moderate reactions may be re-challenged with premedication and close monitoring.[4]
• Complications of Allogeneic Hematopoietic Stem Cell Transplant (HSCT): There is a significant risk of fatal and serious complications, including hyperacute graft-versus-host disease (GVHD), veno-occlusive disease (VOD), and steroid-requiring febrile syndrome, in patients who receive allogeneic HSCT either before or after treatment with a PD-1 inhibitor like Nivolumab. Careful risk-benefit assessment is required in this population.[6]
• Embryo-Fetal Toxicity: Based on its mechanism of action and animal studies, Nivolumab can cause fetal harm when administered to a pregnant woman. The PD-1/PD-L1 pathway is critical for maintaining maternal-fetal tolerance. Females of reproductive potential must be advised of the potential risk to a fetus and should use effective contraception during treatment and for at least 5 months after the final dose.[2]

Comparative Analysis and Market Positioning

Nivolumab (Opdivo®) operates in a competitive immuno-oncology market, with its primary competitor being Pembrolizumab (Keytruda®). Understanding their similarities, differences, and relative positioning is crucial for clinicians, payers, and analysts.

Nivolumab (Opdivo) vs. Pembrolizumab (Keytruda)

Nivolumab and Pembrolizumab are the two leading anti-PD-1 monoclonal antibodies and are often viewed as interchangeable in clinical practice, though important distinctions exist.[40]

• Mechanism and Class: Both drugs belong to the same class of immune checkpoint inhibitors. They are both humanized IgG4 monoclonal antibodies that bind to the PD-1 receptor, blocking its interaction with PD-L1 and PD-L2, and thereby activating an anti-tumor immune response.[40]
• Indications: There is substantial overlap in their approved indications, with both drugs being FDA-approved for at least 10 major cancer types, including melanoma, NSCLC, RCC, cHL, SCCHN, and urothelial carcinoma.[41] However, Pembrolizumab has secured approvals in several indications where Nivolumab has not, such as cervical cancer, endometrial cancer, and triple-negative breast cancer, giving it a broader label in certain areas.[41]
• Dosing Schedules: The administration schedules differ, which can impact patient convenience and healthcare logistics. Nivolumab is typically administered intravenously every 2, 3, or 4 weeks, depending on the dose and indication. Pembrolizumab is administered every 3 or 6 weeks.[41]
• Efficacy: In the absence of large, head-to-head randomized trials for most overlapping indications, comparing efficacy is challenging and relies on cross-trial comparisons, network meta-analyses, and real-world evidence.[42] For example, in a cohort study of advanced melanoma, first-line treatment with the Nivolumab-ipilimumab combination was associated with a numerically longer mean treatment-free survival (12.4 months) compared to Pembrolizumab monotherapy (11.1 months).[44] In contrast, a real-world study in advanced hepatocellular carcinoma found comparable efficacy and safety between the two agents.[43] In first-line NSCLC, where both Pembrolizumab monotherapy and the Nivolumab-ipilimumab combination are options for PD-L1 positive patients, matched-adjusted indirect comparisons have been conducted to inform clinical decision-making.[42] Ultimately, the choice often depends on the specific clinical scenario, biomarker status, and physician/patient preference.
• Safety and Patient Ratings: The safety profiles of the two drugs are very similar, dominated by the same spectrum of immune-related adverse events. Some patient-reported data suggest minor differences, with headache being slightly more common with Opdivo and hypothyroidism more common with Keytruda.[41] In user ratings on Drugs.com, Nivolumab holds a slightly higher average score (5.9 out of 10 from 142 ratings) compared to Pembrolizumab (5.0 out of 10 from 257 ratings).[45]

Table 6: Comparative Profile: Nivolumab (Opdivo®) vs. Pembrolizumab (Keytruda®)

Feature	Nivolumab (Opdivo®)	Pembrolizumab (Keytruda®)	Source(s)
Active Ingredient	Nivolumab	Pembrolizumab	41
Drug Class	Anti-PD-1 IgG4 mAb	Anti-PD-1 IgG4 mAb	40
Dosing Schedules	IV infusion every 2, 3, or 4 weeks	IV infusion every 3 or 6 weeks	41
Key Unique FDA-Approved Indications	Malignant Pleural Mesothelioma (with ipilimumab)	Cervical Cancer, Endometrial Cancer, Triple-Negative Breast Cancer, Primary Mediastinal Large B-cell Lymphoma	41
Comparative Data Summary	Melanoma: Nivo+Ipi combo showed numerically longer treatment-free survival vs. Pembro mono. HCC: Real-world data suggests comparable efficacy. NSCLC: Indirect comparisons needed to guide choice between Nivo+Ipi vs. Pembro mono.	Melanoma: Pembro mono showed reduced risk of death vs. Ipi mono. NSCLC: Pembro mono showed longer OS vs. chemo in PD-L1 high patients.	40
User Rating (Drugs.com)	5.9 / 10 (142 ratings)	5.0 / 10 (257 ratings)	45
Common Differentiating Side Effects (Mild)	Headache, upper respiratory infections	Hypothyroidism	41

Cost-Effectiveness and Patient Access

The high cost of checkpoint inhibitors is a significant factor in their clinical use and market positioning.

• Treatment Cost: The list price, or Wholesale Acquisition Cost (WAC), for Nivolumab is substantial. A single 240 mg infusion has a list price of approximately $7,787, while a 480 mg infusion is listed around $15,574.[46] Cost-effectiveness analyses from Canada have cited a price of $19.55 per mg, leading to a 21-day cycle cost of around $7,431 for Nivolumab monotherapy.[47] It is critical to note that these list prices do not reflect the actual cost to patients or payers after rebates, discounts, and insurance coverage.
• Insurance Coverage: As Nivolumab is administered intravenously in a clinical setting, it is covered under a patient's medical benefit, not their pharmacy benefit. For patients with Original Medicare, this falls under Part B. After the annual Part B deductible is met, Medicare typically covers 80% of the approved cost, with the patient responsible for the remaining 20% coinsurance. Many patients have supplemental insurance (Medigap) or a Medicare Advantage (Part C) plan that helps cover this coinsurance.[46]
• Cost-Effectiveness Analysis: The economic value of Nivolumab is a subject of ongoing study. A cost-effectiveness analysis comparing Nivolumab and Pembrolizumab for head and neck cancer found that the choice depends heavily on the patient's body weight (when using weight-based dosing) and the healthcare system's willingness-to-pay (WTP) threshold. For example, at a WTP of $100,000 per quality-adjusted life-year (QALY), weight-based Nivolumab was found to be more cost-effective for patients weighing less than 72 kg, while Pembrolizumab was preferred for heavier patients.[21] Other analyses have suggested that substantial price reductions of up to 95% might be necessary for Nivolumab combinations to be considered cost-effective at a $50,000/QALY threshold in some indications.[49]
• Patient Assistance Programs: To mitigate the financial burden on patients, the manufacturer, Bristol Myers Squibb, offers comprehensive support programs. BMS Access Support® is a program for commercially insured patients that provides benefits investigation, prior authorization support, and a co-pay assistance program. This program can reduce out-of-pocket costs for eligible patients to as little as $0 per infusion, up to an annual maximum benefit.[39] For uninsured or underinsured patients facing financial hardship, the Bristol Myers Squibb Patient Assistance Foundation (BMSPAF), an independent, non-profit organization, can provide the medication free of charge to those who meet the eligibility criteria.[51]

Future Directions and Conclusion

Ongoing Research and Future Outlook

The clinical development of Nivolumab continues to evolve, with research focused on optimizing its use, expanding its applications, and improving patient convenience.

• Novel Formulations and Dosing: The recent approval of the subcutaneous formulation, Opdivo Qvantig, is a major advancement that significantly reduces administration time and patient burden.[14] This innovation may pave the way for at-home administration in the future, further transforming the patient experience. Concurrently, based on the drug's saturation kinetics and long half-life, clinical trials are actively investigating extended dosing intervals (e.g., every 8 weeks) to see if efficacy can be maintained with less frequent administration, which could further improve convenience and reduce costs.[22]
• New Combinations: The future of immuno-oncology lies in rational combination therapies that target complementary resistance pathways. Research is actively exploring Nivolumab in novel pairings. A key example is its combination with relatlimab, a LAG-3 inhibitor, which has already been approved as a fixed-dose combination (Opdualag™) for melanoma, demonstrating that blocking two distinct immune checkpoints can enhance efficacy.[9] Numerous other trials are evaluating Nivolumab with other immunotherapies (e.g., GM-CSF), targeted agents (e.g., cabozantinib in new tumor types), and radiotherapy to further improve patient outcomes.[54]
• Biomarker Development: A persistent challenge in immuno-oncology is identifying which patients will benefit most from treatment. While PD-L1 expression and MSI-H/dMMR status are established biomarkers, they are imperfect predictors of response.[2] The initial difficulty in correlating PD-L1 levels with response has led to a more nuanced understanding of its role, but the search for more robust predictive biomarkers continues. Future research will focus on integrating multi-omic data, such as tumor mutational burden (TMB), gene expression signatures, and analysis of the tumor microenvironment, to develop more sophisticated predictive models for patient stratification.[55]

Concluding Remarks

Nivolumab has unequivocally established itself as a foundational pillar of modern cancer therapy. Its introduction marked a paradigm shift, moving away from direct cytotoxicity and toward harnessing the patient's own immune system to fight disease. This elegant mechanism of PD-1 checkpoint blockade has translated into unprecedented and durable survival benefits for patients across a vast and growing list of malignancies, from melanoma and lung cancer to mesothelioma and Hodgkin lymphoma.

This remarkable success, however, is balanced by a unique set of challenges. The management of immune-related adverse events, the direct consequence of the drug's powerful on-target activity, requires constant vigilance, specialized expertise, and robust patient education. The complexities of patient selection continue to evolve, with ongoing efforts to refine the use of existing biomarkers like PD-L1 and to discover novel predictors that can better guide therapeutic decisions. Finally, the high cost of treatment necessitates a continuous dialogue about value, cost-effectiveness, and equitable access, a challenge mitigated in part by comprehensive patient support programs.

The trajectory of Nivolumab points toward a future of continued refinement and optimization. Through the development of more convenient subcutaneous formulations, the exploration of rational, synergistic combinations, and a deeper, biomarker-driven understanding of tumor immunology, Nivolumab is poised to remain a vital component of the oncologic armamentarium, offering the chance for longer, better lives to cancer patients worldwide.

Works cited

1. Nivolumab: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 7, 2025, https://go.drugbank.com/drugs/DB09035
2. Nivolumab - Wikipedia, accessed July 7, 2025, https://en.wikipedia.org/wiki/Nivolumab
3. www.ncbi.nlm.nih.gov, accessed July 7, 2025, https://www.ncbi.nlm.nih.gov/books/NBK567801/#:~:text=Nivolumab%20is%20a%20monoclonal%20antibody,T%2Dcells%20against%20cancerous%20cells.
4. Nivolumab - StatPearls - NCBI Bookshelf, accessed July 7, 2025, https://www.ncbi.nlm.nih.gov/books/NBK567801/
5. Opdivo (nivolumab) FDA Approval History - Drugs.com, accessed July 7, 2025, https://www.drugs.com/history/opdivo.html
6. OPDIVO (nivolumab) Label - accessdata.fda.gov, accessed July 7, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125554s095lbl.pdf
7. Nivolumab (intravenous route) - Mayo Clinic, accessed July 7, 2025, https://www.mayoclinic.org/drugs-supplements/nivolumab-intravenous-route/description/drg-20127723
8. OPDIVO® (nivolumab), accessed July 7, 2025, https://www.opdivo.com/
9. Nivolumab - PubChem, accessed July 7, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Nivolumab
10. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor, accessed July 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5332892/
11. Definition of nivolumab - NCI Drug Dictionary, accessed July 7, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nivolumab
12. nivolumab - Cancer Care Ontario, accessed July 7, 2025, https://www.cancercareontario.ca/en/system/files_force/nivolumab.pdf
13. Opdivo® (Nivolumab) - Melanoma Research Alliance, accessed July 7, 2025, https://www.curemelanoma.org/patient-eng/melanoma-treatment/options/opdivo-nivolumab
14. FDA Approves Subcutaneous Injection of Nivolumab, Hyaluronidase-nvhy for NSCLC, Other Solid Tumor Indications - Lung Cancers Today, accessed July 7, 2025, https://www.lungcancerstoday.com/post/fda-approves-subcutaneous-injection-of-nivolumab-hyaluronidase-nvhy-for-nsclc-other-solid-tumor-indications
15. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy, accessed July 7, 2025, https://jitc.bmj.com/content/4/1/72
16. Pharmacodynamics and pharmacokinetics of nivolumab | Download Table - ResearchGate, accessed July 7, 2025, https://www.researchgate.net/figure/Pharmacodynamics-and-pharmacokinetics-of-nivolumab_tbl1_318669580
17. Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma - PMC, accessed July 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4665056/
18. Opdivo (nivolumab) dosing, indications, interactions, adverse effects, and more, accessed July 7, 2025, https://reference.medscape.com/drug/opdivo-nivolumab-999989
19. OPDIVO (nivolumab) injection Label - accessdata.fda.gov, accessed July 7, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s112lbl.pdf
20. Pharmacokinetics and clinical outcomes of low-dose nivolumab relative to conventional dose in patients with advanced cancer - PubMed, accessed July 7, 2025, https://pubmed.ncbi.nlm.nih.gov/39060628/
21. Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - JAMA Network, accessed July 7, 2025, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779575
22. Study Details | Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers | ClinicalTrials.gov, accessed July 7, 2025, https://www.clinicaltrials.gov/study/NCT04295863
23. Big News: FDA Approves Opdivo (Nivolumab) for Lung Cancer, accessed July 7, 2025, https://www.cancerresearch.org/blog/march-2015/fda-approves-opdivo-nivolumab-for-lung-cancer
24. U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer, accessed July 7, 2025, https://news.bms.com/news/details/2025/U-S--Food-and-Drug-Administration-Approves-Opdivo-nivolumab-plus-Yervoy-ipilimumab-as-a-Treatment-for-Patients-with-Previously-Untreated-Microsatellite-Instability-High-or-Mismatch-Repair-Deficient-Unresectable-or-Metastatic-Colorectal-Cancer1/default.aspx
25. FDA-approved indications for OPDIVO® (nivolumab) and OPDIVO in combination with other therapeutic agents, accessed July 7, 2025, https://www.ajmc.com/ipubs/checkmate-77t-in-peri-operative-nsclc/FDA_Approved_Indications_062424.pdf
26. FDA Approves Injectable Nivolumab, an Alternative to IV Infusion - National Cancer Institute, accessed July 7, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2025/fda-opdivo-injection
27. Opdivo, INN- nivolumab - EMA, accessed July 7, 2025, https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf
28. EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC | ESMO, accessed July 7, 2025, https://www.esmo.org/oncology-news/ema-recommends-extension-of-therapeutic-indications-for-nivolumab-and-ipilimumab-to-unresectable-or-advanced-hcc
29. EMA Recommends Extension of Indications for Nivolumab to Include First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma | ESMO, accessed July 7, 2025, https://www.esmo.org/oncology-news/ema-recommends-extension-of-indications-for-nivolumab-to-include-first-line-treatment-of-adult-patients-with-unresectable-or-metastatic-urothelial-carcinoma
30. Nivolumab | European Medicines Agency - PharmGKB, accessed July 7, 2025, https://www.pharmgkb.org/literature/15133302
31. European Commission Approves Perioperative Nivolumab and Chemotherapy for Resectable PD-L1+ NSCLC - OncLive, accessed July 7, 2025, https://www.onclive.com/view/european-commission-approves-perioperative-nivolumab-and-chemotherapy-for-resectable-pd-l1-nsclc
32. Opdivo | European Medicines Agency (EMA), accessed July 7, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo
33. Key clinical-trial evidence for nivolumab - DermNet, accessed July 7, 2025, https://dermnetnz.org/topics/key-clinical-trial-evidence-for-nivolumab
34. Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer - AACR Journals, accessed July 7, 2025, https://aacrjournals.org/clincancerres/article/22/15/3713/79334/Nivolumab-and-Pembrolizumab-for-Non-Small-Cell
35. What is the approval history and clinical development pathway of Opdivo?, accessed July 7, 2025, https://synapse.patsnap.com/article/what-is-the-approval-history-and-clinical-development-pathway-of-opdivo
36. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma - PubMed, accessed July 7, 2025, https://pubmed.ncbi.nlm.nih.gov/27450183/
37. OPDIVO® (nivolumab) | Healthcare Professional Website, accessed July 7, 2025, https://www.opdivohcp.com/
38. Nivolumab Patient Handout - x FACT SHEET, accessed July 7, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Nivolumab_handout.pdf
39. Patient Programs | OPDIVO® (nivolumab), accessed July 7, 2025, https://www.opdivohcp.com/resources/patient-access-financial-support
40. Pembrolizumab vs. nivolumab: How do they compare? - Drugs.com, accessed July 7, 2025, https://www.drugs.com/medical-answers/pembrolizumab-nivolumab-compare-3554067/
41. Opdivo vs. Keytruda: What's the difference? - Medical News Today, accessed July 7, 2025, https://www.medicalnewstoday.com/articles/drugs-opdivo-vs-keytruda
42. Full article: Indirect Comparison of Pembrolizumab Monotherapy Versus Nivolumab + Ipilimumab in First-Line Metastatic Lung Cancer - Taylor & Francis Online, accessed July 7, 2025, https://www.tandfonline.com/doi/full/10.2217/imt-2021-0273
43. Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma - PMC, accessed July 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10463359/
44. Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma | Oncology | JAMA Network Open, accessed July 7, 2025, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2806504
45. Keytruda vs Nivolumab Comparison - Drugs.com, accessed July 7, 2025, https://www.drugs.com/compare/keytruda-vs-nivolumab
46. Opdivo and Medicare: Coverage, options, and costs - MedicalNewsToday, accessed July 7, 2025, https://www.medicalnewstoday.com/articles/does-medicare-cover-opdivo
47. Table 3, Cost and Cost-Effectiveness - Nivolumab (Opdivo) - NCBI Bookshelf, accessed July 7, 2025, https://www.ncbi.nlm.nih.gov/books/NBK596614/table/t03/
48. Medicare Coverage for Opdivo - Healthline, accessed July 7, 2025, https://www.healthline.com/health/medicare/does-medicare-cover-opdivo
49. Table 4, Cost and Cost-Effectiveness - Nivolumab (Opdivo) - NCBI Bookshelf, accessed July 7, 2025, https://www.ncbi.nlm.nih.gov/books/NBK596647/table/t04/?report=objectonly
50. Co-Pay and Financial Support Options - BMS Access Support, accessed July 7, 2025, https://www.bmsaccesssupport.com/patient/co-pay-financial-support
51. Bristol-Myers Squibb Patient Assistance Foundation (BMSPAF) - Requirements & Forms (2025) - PrescriberPoint, accessed July 7, 2025, https://prescriberpoint.com/therapies/nulojix-c16ac64/financial-assistance/bristol-myers-squibb-patient-assistance-foundation-bmspaf
52. Get help paying for your medicines - Bristol Myers Squibb, accessed July 7, 2025, https://www.bms.com/patient-and-caregivers/get-help-paying-for-your-medicines.html
53. Access & Support | Opdualag™ (nivolumab and relatlimab-rmbw) for HCPs, accessed July 7, 2025, https://www.opdualaghcp.com/support-access
54. Clinical Trials Using Nivolumab - National Cancer Institute, accessed July 7, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/nivolumab?pn=1
55. An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers - PubMed, accessed July 7, 2025, https://pubmed.ncbi.nlm.nih.gov/27548326/
56. Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma | Journal for ImmunoTherapy of Cancer, accessed July 7, 2025, https://jitc.bmj.com/content/13/1/e010059